MARKET PULSE-Amber, Borderfree, Endocyte, Intermune, broadcaster stocks
(For more market insights, including options activity, click on ; for the Day Ahead newsletter link.reuters.com/mex49s; for the Morning Call newsletter link.reuters.com/nex49s) U.S. stocks rose on Friday with major indexes on track for a week of strong gains, but geopolitical concerns remained in view as the tenuous situation in Ukraine continued. The Dow Jones industrial average was up 0.73 percent at 16,450.37, the S&P 500 was up 0.57 percent at 1,882.7 and the Nasdaq Composite was down 0.01 percent at 4,318.7.
** ENDOCYTE INC, $29, +98.09 pct
The U.S. drug developer said its experimental drug improved survival rates in lung cancer patients without the disease worsening, when used in combination with an approved treatment.
** SOLARCITY CORP, $66.99, -3.68 pct
SolarCity shares continued to fall for the third consecutive day after the company on Tuesday forecast that its operating costs would more than double in the first quarter. "This has led analysts to reduce estimates, and clearly many investors were disappointed in the rising costs as well," said Raymond James analyst Pavel Molchanov. SolarCity, the largest residential solar installer in the United States, had said in February it expects to install fewer panels in a seasonally weak first quarter due to cold weather.
** HERBALIFE LTD, $49.71, -2.13 pct
Brokerage Argus Reasearch Co cut its rating on the nutritional supplements and weight loss product maker's stock to "hold," citing the Federal Trade Commission's investigation into the company's business practices, including its operations in China. "In view of the protracted challenges caused by the investigation and (William) Ackman's campaign against the company, we are lowering our near-term rating to hold," analyst John Staszak wrote in the note. Continued...